Business
Use of Parsortix in GANNET53 drug trial
Use of Parsortix in GANNET53 drug trial.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 4571F Angle PLC 28 July 2016 \n\n\n\n\n\nFor immediate release\n\n\n 28 July 2016\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nUSE OF PARSORTIX IN GANNET53 DRUG TRIAL IN OVARIAN CANCER \n \nOver 400 blood samples already processed from 136 ovarian cancer patients\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that its Parsortix system has been formally adopted in the ongoing European wide GANNET53 drug trial, an ovarian cancer study.\n \nGANNET53 is a large scale FP7 research project funded by the European Commission investigating use of the drug Ganetespib in metastatic, p53 mutant, platinum-resistant ovarian cancer. The project started in October 2013 and runs for 5.5 years with a budget of €6 million. The molecular results in relation to GANNET53 outcomes will be available at the end of the trial in 2019. More details about the trial are given below. \n \nThe Medical University of Vienna, under the leadership of Professor Robert Zeillinger is responsible for the Companion Diagnostics part of the trial, which stipulates that \"CTC analysis before and during experimental therapy will be performed and evaluated for its value to monitor responsiveness to Ganetespib\". The Medical University of Vienna team has worked for many years with a wide range of CTC systems, both those commercially available from ANGLE's competitors and new technologies under development including commercial and academic systems. Due to lack of suitable cell surface markers, antibody-based CTC systems are ineffective for ovarian cancer. The best result that has been obtained to date with other non-antibody based systems is a CTC detection sensitivity level of 24.5% (i.e. capturing CTCs from only one quarter of ovarian cancer patients). \n \nFollowing the Medical University of Vienna's results with ANGLE's Parsortix system showing \"unprecedented sensitivity and specificity\" announced on 27 January 2015, ANGLE were invited by the consortium to participate in the study. The Medical University of Vienna commenced testing of GANNET53 blood samples for CTCs using Parsortix in May 2015. ANGLE's participation is through the provision of Parsortix loan instruments and cassettes. \n \nThe key objectives...